Michael Kavanaugh, M.D. joined CytomX in January 2015 as senior vice president, chief scientific officer and head of research and early development. Prior to joining CytomX, Dr. Kavanaugh was senior vice president and chief scientific officer of Five Prime Therapeutics. Since joining the company in 2009, he held multiple positions in research and development and led the growth of the company’s therapeutic pipeline. Before Five Prime, Dr. Kavanaugh served as vice president of Novartis Vaccines & Diagnostics, Inc. and executive director of Oncology Biologics in the Novartis Institutes of Biomedical Research. He joined Novartis in 2006 as part of the company’s acquisition of the Chiron Corporation, where he was vice president and head of antibody and protein therapeutics research. Dr. Kavanaugh received his medical doctorate from Vanderbilt University and his bachelor’s degree in molecular biochemistry and biophysics from Yale University. He completed training in internal medicine, cardiovascular disease and molecular and cellular biology at the University of California, San Francisco and the Cardiovascular Research Institute. Dr. Kavanaugh also currently serves as an attending staff physician at the San Francisco Veterans Administration Medical Center and as an associate clinical professor of medicine at UCSF.